Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

Fig. 2

Comparison of cancer-cell recognition by A*02-restricted NY-ESO-1-specific CD4+CD8+ double-positive 19305DP and CD8+ single-positive CD8SP. a IFN-γ production from 19305DP and CD8SP (CD8SP1) against A*02+NY-ESO-1+ melanoma cell lines (SK-MEL-37 and A375) was determined by intracellular cytokine staining. b The reactivity of 19305DP and CD8SP against a panel of cancer cell lines with different A*02 (A2) and NY-ESO-1 (ESO) expression was tested by intracellular IFN-γ staining. c A*02/NY-ESO-1157-165 tetramer binding and TCR Vβ expression was determined by flow cytometry. Cw*03-restricted NY-ESO-1-specific CD8+ T-cell clone and Cw*03/NY-ESO-192-100 tetramer were used as controls to demonstrate specific tetramer binding. d The effect of blocking antibodies for MHC class I (αHLA-A,B,C), MHC class II (αHLA-DP,DQ,DR), CD4 (αCD4) or CD8 (αCD8) on recognition of the indicated melanoma cell lines was investigated by intracellular IFN-γ staining. The data was represented as % recognition as compared to the recognition without antibodies (−). *p < 0.05 compared without antibody treatment

Back to article page